RCM
ELDN icon

RA Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

RA Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,566,338
Closed -$9.24M – 73
2025
Q3 		$9.24M Hold
3,566,338
– – 0.11% 51
2025
Q2 		$9.66M Hold
3,566,338
– – 0.16% 47
2025
Q1 		$12.1M Hold
3,566,338
– – 0.2% 60
2024
Q4 		$14.7M Buy
+3,566,338
New +$14.1M 0.2% 67

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

RA Capital Management's ELDN Position: Q4 2025 in Review

RA Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q4 2025, closing a stake of 3,566,338 shares — an estimated $9.24M sold.

RA Capital Management first reported a position in ELDN in Q4 2024 and held it in 4 quarters. The position peaked at $14.7M in Q4 2024. 95 funds tracked by Wall St. Rank hold ELDN as of Q4 2025.

  • RA Capital Management reported no remaining Eledon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • RA Capital Management sold 3,566,338 Eledon Pharmaceuticals shares in Q4 2025, an estimated $9.24M.
  • RA Capital Management first reported a position in Eledon Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • RA Capital Management's Eledon Pharmaceuticals position peaked at $14.7M in Q4 2024.
  • 95 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2025.

Based on RA Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.